Martin Shkreli

Martin Shkreli
House Committee on Oversight and Government Reform · Public domain · source
Name	Martin Shkreli
Birth date	January 17, 1983
Birth place	Brooklyn, New York City, New York, United States
Nationality	American
Occupation	Businessman, former hedge fund manager, pharmaceutical executive

Martin Shkreli

Martin Shkreli (born January 17, 1983) is an American former hedge fund manager and pharmaceutical executive known for founding and leading biopharmaceutical and investment firms and for attracting public scrutiny over pricing and securities conduct. He rose to prominence in the 2010s through corporate actions at firms and frequent media appearances, provoking responses from regulators, legislators, journalists, and advocacy groups.

Early life and education

Shkreli was born in Brooklyn, New York City, and raised in the neighborhoods of Midwood and Sheepshead Bay, New York. He is the son of Albanian immigrants who emigrated to the United States after the collapse of communist regimes in Eastern Europe; his family background intersects with communities linked to Albania and the Albanian diaspora. He attended Forest Hills High School before enrolling at private institutions and later matriculating at Baruch College in Manhattan, where he studied business and finance. During his youth he participated in entrepreneurial ventures and early trading that presaged later roles at hedge funds and venture-backed firms.

Career in pharmaceuticals and finance

Shkreli began his career in hedge fund management and biotechnology investment, working at firms influenced by practices common to hedge funds and private equity on Wall Street and in Manhattan. He co-founded and managed investment vehicles and funds, including ventures that invested in pharmaceutical development and biotechnology startups associated with drug discovery and licensing deals. He later founded several companies in the pharmaceutical sector, taking executive positions at firms that pursued acquisition, restructuring, and pricing strategies for branded medicines and specialty pharmaceuticals. His corporate leadership connected him with executives and boards typical of the biotech industry, mergers and acquisitions advisors, and investor networks in New York City and beyond.

Controversies and legal issues

Shkreli became a focal point in public debates over drug pricing after corporate actions involving price adjustments for certain marketed pharmaceuticals and histories of patent, licensing, and formulary negotiation tactics. Those pricing decisions attracted scrutiny from United States lawmakers, including hearings and inquiries by members of the United States Congress, and commentary from public health advocacy organizations and media outlets such as The New York Times, The Wall Street Journal, and The Washington Post. Concurrently, regulatory agencies and law enforcement entities conducted investigations into his business practices and securities disclosures, involving prosecutors associated with the United States Attorney for the Eastern District of New York and investigators from federal agencies accustomed to probing complex financial and corporate schemes. Media coverage connected his actions to broader controversies involving pharmaceutical firms like Turing Pharmaceuticals and industry debates involving insurers, hospital systems, and pharmacy benefit managers.

Criminal conviction and imprisonment

Prosecutors charged Shkreli with securities fraud and related offenses tied to trading and fundraising conduct at investment vehicles he managed and leadership roles at corporate entities under his control. The case proceeded through grand jury investigations, pretrial motions, and a federal trial in the United States District Court system, with judges and juries examining evidence including emails, financial statements, and witness testimony. A criminal conviction followed on several counts, leading to sentencing by a federal judge and an order for incarceration in the federal prison system overseen by the Federal Bureau of Prisons. His prosecution and sentence were covered extensively by national news organizations and prompted commentary from legal analysts, civil litigators, and scholars of white-collar crime such as those affiliated with Harvard Law School, Yale Law School, and other academic centers studying corporate misconduct.

Public persona, media and cultural impact

Shkreli cultivated a provocative public persona via social media platforms and interviews with commentators and programs on outlets including Fox News, MSNBC, CNN, and digital channels. His notoriety influenced portrayals in popular culture, inspiring documentaries, investigative reporting series, and references in entertainment industry productions and satire tied to personalities such as John Oliver, Stephen Colbert, and writers for late-night programs. Coverage by investigative journalists at publications like ProPublica, Bloomberg News, and The Atlantic explored intersections between pharmaceutical pricing, regulatory frameworks such as those enforced by the Food and Drug Administration, and public policy debates led by lawmakers including members of the United States Senate and the United States House of Representatives. His case informed legislative proposals and hearings concerning drug pricing reform initiated by policymakers in Washington, D.C., and influenced discussions at think tanks and public health institutions.

Personal life and post-release activities

Shkreli's personal life—residence choices, interactions with investors, and relationships—was reported by business and lifestyle sections of outlets like Forbes, Vanity Fair, and The New Yorker. Following his release from federal custody, he engaged in activities including online commentary, interactions with libertarian and free-market commentators, and involvement with digital asset discourse and entrepreneurial ventures linked to technology and fundraising communities such as those surrounding Silicon Valley startups and blockchain-related projects. His post-release conduct continued to draw attention from regulatory bodies and media organizations, prompting ongoing coverage and analysis by financial commentators and public policy experts.

Category:American businesspeople Category:People from Brooklyn Category:People convicted of fraud